Cassava Sciences CEO Remi Barbier resigns; Rick Barry named Executive Chairman; CEO search begins

FILANA THERAPEUTICS, INC.

CEO/President Remi Barbier resigns effective Sep 13, 2024; also resigns as Chairman and Board member immediately.
SVP Neuroscience Lindsay Burns steps down; enters 1-year consulting agreement at $500/hour; receives $0.5M severance.
Independent director Rick Barry appointed Executive Chairman and principal executive officer; CEO search launched.
Board adds Pierre Gravier as Audit Committee Chair, Robert Anderson as Nominating & Governance Committee Chair.
Company pledges enhanced transparency: quarterly analyst calls and timely posting of Phase 3 trial results to clinicaltrials.gov.

item 5.02 item 7.01 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Remi Barbier

Chairman of the Board

FLNA · FILANA THERAPEUTICS, INC.

Effective: 2024-07-15
Filed: July 17, 2024, 7:59 PM ET

In addition, on July 15, 2024, the Company’s Board of Directors (the “ Board ”) accepted Mr. Barbier’s resignation as Chairman of the Board and from board membership, effective immediately.

Departed

Remi Barbier

President and Chief Executive Officer

FLNA · FILANA THERAPEUTICS, INC.

Effective: 2024-09-13
Filed: July 17, 2024, 7:59 PM ET

On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024

Appointed (interim)

Richard J. Barry

Executive Chairman

FLNA · FILANA THERAPEUTICS, INC.

Effective: 2024-07-15
Filed: July 17, 2024, 7:59 PM ET

On July 15, 2024, Richard J. Barry, an independent director and currently the Chair of the Company’s Audit and Nominating & Governance Committees, was appointed by the Board as its Executive Chairman.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Remi Barbier resigned as Chairman of the Board at FILANA THERAPEUTICS, INC..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

In addition, on July 15, 2024, the Company’s Board of Directors (the “ Board ”) accepted Mr. Barbier’s resignation as Chairman of the Board and from board membership, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Remi Barbier resigned as President and Chief Executive Officer at FILANA THERAPEUTICS, INC..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard J. Barry was appointed as Executive Chairman at FILANA THERAPEUTICS, INC..

Action: appointed
Role: Executive Chairman

Exact text from the filing

On July 15, 2024, Richard J. Barry, an independent director and currently the Chair of the Company’s Audit and Nominating & Governance Committees, was appointed by the Board as its Executive Chairman.

View on SEC.gov

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-022876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.